优化PD-L1阳性EGFR突变非小细胞肺癌一线TKI疗效：抗血管生成药物影响（Table1）

数据集获取（Figshare）

• 源站标题：Table1_Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents.DOCX
• DOI：10.3389/fphar.2024.1391972.s001
• 发布日期：2024-08-05
• 文件数：1 个
• 文件总体积：32.02 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table1_Optimizing_first-line_TKI_treatment_efficacy_in_PD-L1-positive_EGFR-mutated_NSCLC_the_impact_of_antiangiogenic_agents_DOCX/26493643

命令行下载

curl -L -o "Table1_Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents.DOCX" "https://ndownloader.figshare.com/files/48170815"

文件清单

• Table1_Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents.DOCX（32.02 KB）

文件总体积 32.02 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundIn individuals receiving treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), those exhibiting positive PD-L1 expression might experience reduced progression-free survival (PFS). However, the effects on overall survival (OS) and the determination of efficacious treatment approaches are still not well-defined.
MethodsIn our retrospective study, we examined data from 193 NSCLC patients with advanced EGFR mutations who received first-line TKI treatments, treated at two centers of Shaw Hospital in Zhejiang, China. This analysis covered a period from 1 January 2016 to 30 April 2023.
ResultsPatients with PD-L1 positivity exhibited a markedly shorter average PFS (9.5 months versus 17.8 months, P For PD-L1-positive patients, combined antiangiogenic treatments and immunotherapy can significantly improve survival outcomes. In contrast, PD-L1-negative patients show less benefit from these therapies, highlighting the greater efficacy of these treatments in PD-L1-positive individuals.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fphar.2024.1391972.s001（source: https://frontiersin.figshare.com/articles/dataset/Table1_Optimizing_first-line_TKI_treatment_efficacy_in_PD-L1-positive_EGFR-mutated_NSCLC_the_impact_of_antiangiogenic_agents_DOCX/26493643）。